C
irculating microvesicles (MVs) are small phospholipid vesicles, released into the bloodstream by virtually all eukaryotic cell types, including erythrocytes, platelets, leukocytes and endothelial cells. 1 Initially underappreciated as cellular "dusts", 2 MVs have more recently been recognized to play vital biological functions, including the facilitation of cell-to-cell interactions, induction of cell signaling and even the transferral of genetic material between different cell types. 3À5 In particular, recent studies have established an integral role for microvesiculation in erythrocyte aging processes. 6 By shedding MVs, erythrocytes eliminate toxic, denatured hemoglobin as well as membrane proteins, which would otherwise lead to early phagocytosis. 7 In stored blood, this process leads to an increase in erythrocyte-derived MVs over time, which suggests that MVs could be potentially used as an indicator of blood product quality. 8 Such applications could have significant clinical implications, considering the growing evidence of transfusion complications associated with aging blood products (e.g., multiple organ failure, 9, 10 increased mortality in critically ill patients, 11 postoperative complications after cardiac surgery 12 ). The lack of sensitive, standardized MV assays poses a significant barrier to implementing MV analyses in routine clinical settings. 13, 14 Flow cytometry has been the method of choice for analyzing MVs due to its high throughput and molecular detection capabilities. 15 Yet, the detection is limited by weak light scattering, because MVs are smaller than the wavelength of light. As a result, flow cytometry measurements severely underestimate total MV counts. Newer counting approaches based on particle-tracking or dynamic light scattering now offer much more accurate MV counts, approximately 10 3 -fold higher than those reported by flow cytometry. 16 However, these methods are unable to provide molecular information on MVs. While conventional protein analyses such as Western blotting and enzyme-linked immunosorbent assays (ELISA) can provide such information, they generally require large numbers of MVs and involve time-consuming isolation processes. To translate MV analyses to routine clinical practice and blood banking, the prevailing challenge is developing simpler and more sensitive sensing technologies. We herein report on the development of a new nanotechnology platform capable of accurate and rapid MV analyses. The system incorporates both microfluidics and magnetic sensing technologies. A microfluidic cartridge directly isolates MVs from blood before labeling them with magnetic nanoparticles (MNPs). The labeled MVs are then detected by a miniaturized micronuclear magnetic resonance (μNMR) system. 17 Processing of an entire sample is performed within the chip, obviating the need for external MV isolation steps (e.g., ultracentrifugation 18 ). Furthermore, because the assay requires only small volumes of blood (<200 μL), it is possible to monitor a given blood product both repeatedly and sequentially. Using the developed platform, we measured MV concentrations as well as MV proteins. Moreover, in a longitudinal study, we found that increased MV counts corresponded with prolonged storage. The protein profile per vesicle, however, displayed negligible changes, indicating an increase of a homogeneous MV population during blood aging. Importantly, MVs were found to contain hemoglobin molecules that exhibit the same capacity for peroxidase-like activity and nitric oxide depletion as cell-free hemoglobin; these findings may help explain the adverse effects often seen in clinical settings with older blood units. On the basis of these findings, we identified erythrocyte-derived MVs as an effective biomarker for monitoring blood product quality.
RESULTS
Assay Platform and Principle. Scanning electron microscopy revealed the presence of budding MVs (<200 nm) on the surface of erythrocytes ( Figure 1A ). To enable reliable detection of such small objects, we used polymer microbeads as a solid support for magnetic targeting ( Figure 1B) . Namely, MVs were first captured on antibody-coated microbeads (diameter, 1 μm) and subsequently labeled with MNPs via secondary antibodies. MNPs and secondary antibodies were modified with tetrazine (TZ) and trans-cyclooctene (TCO), respectively. The fast, covalent cycloaddition between TZ and TCO maximized MNP binding to target MV proteins, and thus served to improve overall detection sensitivity. 19 ,20 The amount of MNPs was then quantified by measuring the transverse relaxation rate (R 2 ) of samples by μNMR; the R 2 value displays a linear increase with MNP concentration, enabling quantitative molecular analyses. 21, 22 The bead-based μNMR detection significantly simplified the assay, as conventional centrifugation or filtration can be used to wash excess reagents. It also showed improved detection sensitivity, compared to the magnetic relaxation switching assay, 22 since no free-floating MNPs are present in the background. To facilitate the developed assay procedure, a microfluidic cartridge was implemented for on-chip MV isolation and labeling. This chip uses membrane filters, which size-selectively isolate MVs from unprocessed blood samples ( Figure 1C) . A capillary layer, inserted underneath the membrane, guides the filtered MVs to the collection channel. The filter and guiding layer are sandwiched between two permanent ring-magnets, which enable easy replacement of filter units when processing large volumes of samples. The size cutoff for the membrane filter is ∼1 μm ( Figure S1 ). The collected MVs are subsequently captured onto beads and labeled with MNPs (see Experimental Section and Figure S2 for details). To provide on-chip processing, we also integrated a microfluidic mixer for fast in-flow conjugation, an in-line filter (pore size: 400 nm) to collect microbeads (1 μm), and torqueassisted valves for fluidic control ( Figure 1D ). Figure 1E shows a photograph of a prototype device. This system can filter 300 μL (150 μL per inlet) of packed red blood cell (pRBC) samples in less than 10 min. Nanoparticle tracking analysis (NTA) of the purified MVs revealed a single population with an average size of 167 nm ( Figure 1F) ; this size was consistent with electron microscopy measurements ( Figure 1A ), and corroborated a likely limitation of detecting MVs with flow cytometry. The collected MVs were then bead-captured and magnetically labeled on-chip ( Figure 1G ). The entire assay took less than 30 min, and thus allowed for real-time analysis of blood samples. μNMR measurements of pRBC samples processed by the microfluidic device were also found to be identical to measurements of samples prepared by ultracentrifugation. This confirmed that the microfluidic device can enrich MVs, and that other proteins in the stored blood supernatant have minimal effect on μNMR measurements.
Assay Optimization: MV Counting and Profiling. We first optimized the assay platform for quantitative MV analyses. To measure MV concentration ([MV]), we chose to target CD235a (Glycophorin A), an abundant protein marker for erythrocytes. 23 Samples were prepared from pRBC units. MVs are first captured on microbeads coated with CD235a antibodies, and subsequently labeled with MNPs for CD235a. For a given [MV], we changed the bead concentration to achieve the maximal R 2 values; the optimal ratio between bead and MV concentrations was found to be ∼1:20. The measured R 2 values (ΔR 2
CD235a
) were linearly proportional to [MV] , which was independently estimated by NTA ( Figure 2A ). Similar measurements on CD235a expression by ELISA and μNMR likewise showed excellent correlations ( Figure 2B ). Importantly, the ΔR 2 We subsequently profiled other protein markers, each selected for their prevalence and potential significance to erythrocyte biology. Three representative markers were screened: (i) CD44, an adhesion receptor implicated in the adhesion of lymphocytes and monocytes to endothelial cells in the sickle cell disease model; 24 (ii) CD47, a marker of self on erythrocytes, whose decrease leads to phagocytosis of senescent erythrocytes; 25, 26 ARTICLE however, remained unchanged over time (P > 0.43, one-way ANOVA; Figure 3A ). The increase in ΔR 2 CD235a could thus be attributed to the increase in MV counts, not to the change in CD235a expression on individual MVs. The expression levels of surface markers also showed negligible changes over their initial values ( Figure 3B ). These findings strongly suggest that highly homogeneous MVs are formed with blood aging. Consistent with this model, the median size of the MVs (estimated by NTA) also remained unchanged for the duration of storage ( Figure S4B ).
We next went on to monitor multiple pRBC units (n = 7) longitudinally, measuring [MV] via R 2 CD235a . All the samples showed a linear increase in [MV] with time (P < 0.002, mixed model; Figure 3C ). Interestingly, the initial [MV] value and its subsequent rise were highly variable among samples. For instance, some pRBC units exhibited higher [MV] values even in the early days of storage compared to other units after ∼40 days ( Figure 3C ). This highlights the importance of monitoring individual blood units serially to evaluate their quality, rather than relying on days of storage as the sole indicator.
MVs Retain Toxicities of Cell-Free Hemoglobin. Cell-free hemoglobin (Hgb) that is not encapsulated within an intact cell membrane could damage vascular systems in transfused hosts by generating reactive oxygen species (ROS) as well as by scavenging a critical vasodilator, nitric oxide (NO).
27À29 Studies have shown adverse effects of plasma hemoglobin, released from hemolysis, in various disease states. 30, 31 However, it remains unclear whether hemoglobin encapsulated within MVs retain similar toxicities to cell-free hemoglobin.
To address this question, we first quantified the Hgb content of MVs. Stored blood samples were processed using the developed microfluidic cartridge, and Hgb concentrations were measured (see Experimental Section for details). The average Hgb contents per MV was measured to be 1.5 Â 10 À15 g ( Figure 4A ). The total amount of MV-derived Hgb increased with storage time as more MVs were formed with blood aging. We next examined whether MV-derived Hgb can generate oxidative stress. Since heme, an integral part of Hgb, is an active element of horseradish peroxidase (HRP), we hypothesized that 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB), which is a commonly used colorimetric substrate 
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for HRP, would be readily oxidized by MVs. Indeed, MVs showed concentration dependent peroxidase-like activity ( Figure 4B ), confirming their capacity for ROS generation. An inhibition assay was also employed to test the extent of NO depletion by MVs. NO in aqueous buffer typically undergoes rapid auto-oxidation to form nitrite (NO 2
Spontaneous NO 2 À production, however, could be inhibited by MV-derived Hgb via the following NO scavenging reactions: Hb þ NO f HbNO; HbO 2 (Fe Figure 4C ).
CONCLUSION
Despite growing evidence describing increased risk of adverse effects with transfusion of older blood units, there is currently no standard test capable of objectively measuring the quality of stored blood units. In the current study, we addressed this need by identifying erythrocyte-derived MVs as a promising marker for monitoring blood aging. In stored blood, homogeneous MV populations were observed to increase over time; both the initial MV level and its temporal changes were observed to vary across blood samples, which made it necessary to test individual blood over time. Importantly, we verified that MVs, like cell-free hemoglobin, have the potential to cause vascular damages through the generation of reactive oxygen species and the consumption of nitric oxide (vasodilator).
To facilitate MV analyses, we implemented a new analytical platform by combining microfluidics with magnetic detection. Although the platform lacks the capacity to resolve individual MVs, it can rapidly quantify MV concentrations as well as detect average expression of target biomarkers. Furthermore, the platform enables efficient isolation of nanoscale MVs directly from stored blood units, and allows for their detection using minimal sample purification steps. These advantages, combined with the portability of the μNMR system (i.e., no bulky instrumentation), 17 render the technology poised for point-of-care testing on blood products. Going forward, we envision that the developed technology could have broad diagnostic value. By facilitating rapid and quantitative molecular analyses of MVs from various cellular origins across disease states, this technology could promote early detection and treatment response monitoring. In turn, the expanded set of cellular and molecular information attained from individual patients could inform personalized medicine strategies.
EXPERIMENTAL SECTION
Packed Red Blood Cell (pRBC) Units and MV Preparation. pRBC units were obtained from the Massachusetts General Hospital (MGH) Blood Bank (Boston, MA). The units were preserved in Adsol solution and were returned to the blood bank after an attempted transfusion (within 30 min of leaving the blood bank). Throughout this time, all units were stored at 4°C. Portions of blood, drawn through a sterile coupler and 25G needle, were processed by the microfluidic devices. As a comparison, MVs were also isolated by serial centrifugations. For this, blood samples were initially centrifuged twice at 2000g for 15 min to remove cellular components before being centrifuged twice again at 100 000g for 70 min to obtain the MVs. The MV pellets were then reconstituted in phosphate buffered saline (PBS) solution.
Microfluidic Device Fabrication and Assembly. The microfluidic devices were fabricated by stacking three layers of polydimethylsiloxane (PDMS; Dow Corning) on a glass slide. The cast molds for the bottom and top layers were prepared by patterning epoxy-based SU8-3050 photoresist (Microchem) via conventional photolithography. A filter PDMS block was also prepared separately by sandwiching a membrane filter (400 nm pore diameter; Nuclepore, Whatman) with two 1 mm-thick PDMS slabs (5 Â 5 mm 2 ). This filter was used to capture microbeads during MV-labeling. The channel patterns and site-locators for torque-actuated valves were contained within the bottom PDMS layer (thickness, 1 mm), while additional fluidic channels were contained within the top PDMS layer (thickness 1 mm). Initially, the PDMS filter block and boltnut pairs (#4-40) were aligned and glued on top of the bottom layer. Uncured PDMS polymer was then poured over the assembly, forming the intermediate layer (final thickness, 2 mm). After the polymer had cured, the top PDMS layer was irreversibly bonded to the intermediate layer via oxygen plasma treatment. Inlet and outlet reservoirs were punched out, and the assembled device was finally bonded irreversibly to a glass slide. 
ARTICLE
For isolating MVs from the pRBC units, a replaceable Vivid Plasma Separation membrane filter (GR grade, Pall Life Sciences), cut into a disk-shape (diameter, 25 mm), was used. A capillary guide (diameter, 25 mm), which collects filtrate, was also patterned onto polyethylene terephthalate (PET) film (thickness, 132 μm) via laser cutting. This filter set was then mounted onto the inlet of the microfluidic device using a pair of ring magnets (K&J Magnetics) as a clamp.
Modification of Microbeads for MV Capture. Antibody coated capture beads were prepared by incubating streptavidin-coated polystyrene particles (1 μm in diameter, Spherotech, SVP-10-5) with biotinylated capture antibody for 30 min before washing in PBS.
Tetrazine (TZ) Modification of Magnetic Nanoparticles (MNPs). Amineterminated cross-linked iron oxide (CLIO) nanoparticles with a hydrodynamic diameter of 21 nm were used for all magnetic labeling. Amino-CLIO was then modified with 2,5-dioxopyrrolidin-1-yl 5- (4-(1,2,4 ,5-tetrazin-3-yl)benzylamino)-5-oxopentanoate (TZ-NHS) to create CLIO-TZ. 19 The reaction was performed in 200-fold excess TZ-NHS relative to amino-CLIO, and proceeded in PBS containing 0.1 M sodium bicarbonate for 3 h at room temperature. Following conjugation, excess TZ-NHS was removed using Sephadex G-50 columns (GE Healthcare).
Antibody Modification with trans-Cyclooctene (TCO). Antibodies were modified with (E)-cyclooct-4-enyl 2,5-dioxopyrrolidin-1-yl carbonate (TCO-NHS), as previously reported. 19 Each antibody was buffer-exchanged into PBS (pH 8.0) using 2 mL Zeba desalting columns (Thermo Fisher). Purified antibodies were then reacted with 1000-fold excess TCO-NHS in 10% dimethylformamide for 3 h at room temperature. TCO conjugated antibodies were subsequently purified by buffer exchange into PBS, and their concentrations were determined by absorbance measurements. The following antibodies were used in this study: human CD235a (Clone GA-R2, BD), CD55 (Clone JS11, Biolegend), CD47 (Clone CC2C6, Biolegend), CD44 (Clone IM7, Biolegend).
MV Labeling with the Microfluidic Cartridge. Samples (100 μL) from each pRBC unit were loaded into the inlets of the fluidic cartridge. Negative pressure was then applied to collect MVs in the reservoir (see Figure S2 for details of device operation). Following MV collection, the MNP-labeling procedure was performed by repeating the following three-step sequence: reagent addition, mixing (binding), and re-collection. For example, to capture MVs on microbeads, the following steps were performed: (1) 1-μm microbeads modified with capture antibodies (CD235a) were introduced into the reservoir containing the MVs. In a 100 μL sample volume, the MV and microbead concentrations were 10 8 to 10 9 MVs and 5 Â 10 7 beads, respectively. (2) The mixture of MVs and microbeads was then flowed through the extended mixing channel. (3) At the end of the mixing channel, the MV-bound beads (MV-beads) were retained by an in-line membrane filter (pore-size: 400 nm). Buffer solution was used to wash. (4) Reverse flow from the buffer inlet was then applied to release and recollect the MV-beads in the reservoir. Similar steps were likewise performed following the addition of mAb-TCO into the reservoir, which resulted in mAb-TCO-MV-beads. Repeating the steps with MNP-TZ ultimately resulted in MVs labeled with MNPs (see Supplementary Methods for illustration of fluidic operation). The entire process could be completed within 30 min.
Micronuclear Magnetic Resonance (μNMR) Measurement. μNMR measurements were performed using a previously described miniaturized NMR relaxometer. 17 The operating magnetic field, generated by a portable permanent magnet, was 0.5 T. The transverse relaxation rate (R 2 ) was measured on 2-μL sample volumes using CarrÀPurcellÀMeiboomÀGill pulse sequences with the following parameters: echo time, 4 ms; repetition time, 1 s; the number of 180°pulses per scan, 50; the number of scans, 8. All measurements were performed in triplicate, and the data are displayed as mean ( SEM.
Comparative Assays. For ELISA measurements, purified MVs were initially captured in antibody coated polystyrene 96-wells before subsequent labeling with biotinylated antibody and streptavidinÀHRP. Following the addition of substrate, chemiluminescence was measured (Safire, Tecan). MV concentrations were also measured by NTA (NanoSight, LM10) as per the manufacturer's instructions.
MV Toxicity Assays. MV samples were prepared by processing pRBC units with the developed microfluidic cartridge. MV concentrations were then estimated following μNMR detection of CD235a. (1) Hgb measurement: MVs were reacted with Drabkin's reagent (Sigma) to convert Hgb to cyanomethemoglobin, before measuring absorbance (540 nm). (2) Peroxidase activity: TMB and peroxidase (Thermo-Fisher) were mixed in equal amounts and the mixture distributed into a 96-well plate. PBS solution containing MVs of different concentrations was then added to each well. Absorbance at 370 nm was measured to estimate peroxidase activity. (3) NO depletion: MVs of varying concentration in PBS were added to a 96-well plate containing freshly prepared 50 mM 1,1-diethyl-2-hydroxy-2-nitrosohydrazine (DEA NONOate). The mixture was incubated on ice for 20 min. Nitrite concentrations were then measured using Griess reagent as per the manufacturer's protocol (Promega).
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